Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2025 07:00 ET | Source: Iantrek, Inc.

Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma

AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients With over 100 surgeon partners and thousands of cases performed throughout the early-release program, Iantrek pioneers...
September 02, 2025 07:00 ET | Source: Iantrek, Inc.

AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases

WHITE PLAINS, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc. today announced the publication of two new peer-reviewed studies that expand the clinical evidence base for AlloFlo™ Uveo,...
August 20, 2025 07:00 ET | Source: Iantrek, Inc.

Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy

Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy, and expand commercial access to match demand.
May 06, 2025 09:48 ET | Source: Iantrek, Inc.

Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo™ Uveo

WHITE PLAINS, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a leader in bio-interventional ophthalmic surgery (BIOS), today announced it has surpassed 2,000 AlloFlo™ Uveo procedures in...
March 18, 2025 09:30 ET | Source: Iantrek, Inc.

Iantrek Announces Positive 2-Year Results Demonstrating Efficacy and Safety of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients

White Plains, March 18, 2025 (GLOBE NEWSWIRE) -- Iantrek Announces Positive 2-Year Results Demonstrating Efficacy and Safety of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement...
February 04, 2025 08:00 ET | Source: Iantrek, Inc.

Iantrek Appoints Adam Szaronos as Chief Executive Officer

WHITE PLAINS, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical technology company pioneering bio-interventional approaches for chronic eye diseases, today announced the appointment...
January 13, 2025 08:00 ET | Source: Iantrek, Inc.

Iantrek Announces First Commercial Cases of its C.Rex Micro-Interventional System for Trabecular Outflow Enhancement

White Plains, NY., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Iantrek, Inc, a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional technologies for the...
December 10, 2024 08:00 ET | Source: Iantrek, Inc.

Iantrek Announces Peer-Reviewed Publication Highlighting 12-Month Safety and Effectiveness Results for its Bio-Interventional Uveoscleral Outflow Technology in Open-Angle Glaucoma Patients

White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and...
September 17, 2024 08:00 ET | Source: Iantrek, Inc.

Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients

WHITE PLAINS, N.Y., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed medical technology company pioneering next-generation bio- and micro-interventional approaches for ophthalmic...
September 11, 2024 08:00 ET | Source: Iantrek, Inc.

Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma

WHITE PLAINS, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the...